antibacterials

Canopus BioPharma, in collaboration with Swinburne University in Australia, has developed a unique anti-bacterial compound derived from the plant Eremophila longifolia (Emubush), for use in the prevention and elimination of cariogenesis, halitosis, gingivitis and periodontitis.

These ethanolic extracts of the traditional Aboriginal medicinal plant inhibit the bacterium Streptococcus mutans and Streptococcus sobrinus, two cariogenic pathogens known to cause dental caries (cariogenesis).

In all tests carried out, the Emubush extract was as effective as chlorhexidine and Listerine and superior to ethanol, ingredients of conventional mouthwashes. Further development involves the formulation of this extract in a mouth wash and other oral hygiene products.

Canopus currently has patents pending for the use of an extract derived from the plant Eremophila longifolia for the prevention and treatment of cariogenesis (dental caries), halitosis (bad breath), gingivitis and periodontitis (gum disease).

 

 

United States Office
Canopus BioPharma Inc
12400 Ventura Blvd
Suite 426,
Studio City
CA 91604
info@canopusbiopharma.com

European Headquarters
Canopus BioPharma Inc
Baybush, Straffan
Co. Kildare, Ireland
Telephone: +353 1 627 2636
Fax: +353 1 627 9028
info@canopusbiopharma.com

Australian Office
Canopus BioPharma Inc
Kenilworth Stn, PO Box 716,
Oxley Street, Bourke,
NSW 2830, Australia
Tel: +61 2 6874 7830
Fax: +61 2 6874 7884

South African Office
Canopus BioPharma Inc
P.O.Box. 92051
Flaming Rock Cresent
Mooikloof 0059
Pretoria